MTX-211 (also known as Mol 211, HY-107364), functioning as a dual inhibitor targeting both epidermal growth factor receptor (EGFR) and phosphoinositide-3 kinase (PI3K), exhibited potent in vivo growth-inhibitory effects against colorectal cancer models characterized by BRAF and KRAS mutations [1]. Here, BRAF is linked to colorectal cancer.